Table 4.
Antiviral activity of TMR and MVC in Participant samples and single clones of Screening, PDVF samples, and site-directed mutants from BRIGHTE.
| Participants | Sample type | TMR polymorphisms | TMR IC50 (nmol/l) | MVC IC50 (nmol/l) | MVC MPI (%) |
| 474 | Screen: Population | M426L | 66 | ND | ND |
| PDVF: Population | S375N, M426L | 372 | ND | ND | |
| 474 | Screening clone | M426L | 234.1 | 135.9 | 88.8 |
| PDVF clone | M426L | 788.9 | 89.6 | 93.5 | |
| Screening clone SDM | none | 1.1 | 169.5 | 91.1 | |
| PDVF clone SDM | none | 1.3 | 166.2 | 93.8 | |
| 203 | Screen: Population | M434T | 9 | ND | ND |
| PDVF: Population | S375N, M426L, M434T | >5000 | ND | ND | |
| 203 | Screening clone | M434T | 69.7 | >5000 | −13.9 |
| PDVF clone | M426L, M434T | >2000 | >5000 | −2.6 | |
| Screening clone SDM | none | 2.2 | >5000 | 6.7 | |
| PDVF clone SDM | M434T | 432.2 | >5000 | −7.3 | |
| PDVF clone SDM | M426L | 171.3 | >5000 | −2.2 | |
| PDVF clone SDM | none | 5.9 | >5000 | −8.1 |
ND, not done.